Cell Therapy Market Companies and their Innovations
The global cell therapy market size was estimated at US$ 4.79 billion in 2023 and is projected to grow to US$ 44.39 billion by 2034, rising at a compound annual growth rate (CAGR) of 22.69% from 2024 to 2034.
Top Companies in the Cell Therapy
- Novartis AG
- 2seventy Bio Inc.
- Anterogen Co., Ltd.
- Johnson & Johnson Services, Inc
- Astellas Pharma Inc.
- M Aurion Biotech
- EDIPOST
- Atara Biotherapeutics
- JCR Pharmaceuticals Co., Ltd.
- S. BIOMEDICS
- Holostem Terapie Avanzate S.r.l
- Bristol-Myers Squibb Company
- JW Therapeutics
- Nkarta, Inc.
- Gilead Sciences, Inc.
Pipeline of 2seventy Bio in the Cell Therapy Market
| Company Name | 2seventy Bio, Inc. |
| Headquarters | Massachusetts, U.S., North America |
| Recent Development | In April 2024, Regeneron Pharmaceuticals, Inc. completed the asset purchase agreement ("APA"), according to 2seventy Bio, Inc. As part of their recently created cell therapies business, Regeneron employed over 160 workers from 2seventy Bio and acquired all of their research and development initiatives related to autoimmune and cancer under the provisions of the American Psychological Association. Moving ahead, 2seventy Bio will work in tandem with their partner Bristol Myers Squibb (BMS) to exclusively concentrate on the marketing and development of Abecma (idecabtagene vicleucel), their BCMA-targeted CAR T cell treatment for multiple myeloma. |
Pipeline of Astellas in the Cell Therapy Market
| Company Name | Astellas Pharma Inc. |
| Headquarters | Tokyo, Japan, North America |
| Recent Development | In May 2024, to create unique convertibleCAR® projects by merging the state-of-the-art cell therapy platforms from both businesses, Astellas Pharma Inc. and Poseida Therapeutics, Inc. have formed a research partnership and licensing agreement. Poseida and Xyphos Biosciences, Inc., a fully owned subsidiary of Astellas, or "Xyphos," have established this arrangement. |
Recent Developments in the Cell Therapy Market
- In April 2024, for the manufacturing of CAR T cell treatments, Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to the production of cell therapies at the clinical and industrial scale, announced a global capacity reserve and supply agreement. Up to $380 million in milestone and upfront payments are part of the transaction's worth.
- In February 2024, the clinical-stage biopharmaceutical company Autolus Therapeutics plc, which is developing next-generation programmed T-cell therapies, and BioNTech SE, which is leading the way in next-generation immunotherapy and developing novel therapies for cancer and other serious diseases, have announced a strategic collaboration to move both companies' autologous CAR-T programs closer to commercialization, subject to regulatory authorizations. The firms signed into a licensing and option agreement as well as a securities purchase agreement in line with their strategic partnership. BioNTech consents to give Autolus $200 million in funding.
- In February 2024, For the purpose of launching its life-saving cell therapy technologies in the US for important cancer studies and potential commercial supply, AstraZeneca committed $300 million to a state-of-the-art facility in Rockville, MD. With an initial focus on producing T-cell treatments to allow for global clinical trials, more than 150 new, highly qualified employment will be created. The website may gradually broaden its scope to include help for more illness categories.
Overview of U.S. Consignee and Shipper Transactions in the Cell Therapy Market
| CONSIGNEE NAME | SHIPPER NAME | PRODUCT DESCRIPTION | QUANTITY | WEIGHT |
| BAUSCH AND LOMB | JANSSEN PHARMACEUTICA NV J AND J PHARMA | PHARMACEUTICALS PHARMACEUTICALS | 19 | 3182 |
| EASTERN TECHNOLOGIES INC | GRI MEDICAL AND ELECTRONIC TECHNOLOGY | SURGICAL DRAPE SURGICAL GOWN SURGICAL PACK TABLE COVER | 739 | 5957 |
| PBC NUTRITIONALS INC | CHAUCER FOODS | FREEZE DRIED SMOOTHIE ORGANICNET WEIGHT:1708.22 KG | 17794 | 4228 |
| NOVO NORDISK US BIO PRODUCTION | NOVO NORDISK A S | PHARMACEUTICALS HIGH VALUE | 372 | 9793 |
| DARBY DENTAL SUPPLY LLC | EURONDA | DENTAL SUPPLIES | 23 | 12101 |
| CALDERON TEXTILES LLC | INTERNATIONAL TEXTILE AND APPAREL INC | PATIENT GOWN | 469 | 8010 |
| CHR HANSEN INC | CHR HANSEN A S | NUTRITIONAL SUPPLEMENTS | 12 | 4273 |
| NATURAL STONE RESOURCES INC | SHRIYA MINING INDUSTRIES S | FIRST GRADE GRANITE TILES & FIRST GRADE SLATESTONE TILES | 20 | 21500 |
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking